Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection. A computerized literature search of PubMed, SCOPUS, EMBASE, EBSCO, Web of science, and Cochrane CENTRAL was conducted using relevant keywords. Data from eligible studies were pooled in a fixed effect meta-analysis model, using OpenMeta[Analyst] software. Pooled data from six randomized trials (n=1427 patients) showed that velpatasvir plus sofosbuvir achieved sustained virological response (SVR12) rates of 98.2% in genotype-1, 99.4% in genotype-2, 94.7% in genotype-3, 99.6% in genotype-4, 97.1% in genotype-5, and 98.8% in genotype-6 patients. The addition of ribavirin did not significantly increase the SVR12 (RR=0.95, 95%CI [0.88, 1.02]) or decrease relapse rates (RR=2.52, 95% CI [0.49, 12.87]) in HCV genotype-1 patients. However, adding ribavirin significantly increased SVR12 (RR=89.5, 95% CI [80.4, 99.5]) in genotype-3 patients. In conclusion, the 12-week regimen of sofosbuvir plus velpatasvir was highly effective in HCV patients, including those with cirrhosis and former treatment experience. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates. Further studies should investigate the effect of adding ribavirin to this regimen, especially in HCV genotype-3 patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jiph.2017.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study.
Front Med (Lausanne)
October 2024
Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Background And Objectives: Direct-acting antiviral (DAA) agents are now widely used to treat patients with hepatitis C infection (HCV) and effectively increase their sustained virologic response (SVR). However, the literature seems to lack or deficient evidence of DAA efficacy in more complicated patients, especially those with HCV reinfection after liver transplantation (LT) or liver-kidney (hepatorenal) transplantation (LKT). This study aimed to retrospectively evaluate the effectiveness of two different DAA regimens in LT and LKT patients with HCV reinfection.
View Article and Find Full Text PDFReal-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Aliment Pharmacol Ther
July 2024
Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).
View Article and Find Full Text PDFThe deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.
Sci Rep
March 2024
Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs. Ribavirin is an antiviral medication used to treat HCV infection.
View Article and Find Full Text PDFGeneralized cost-effectiveness analysis to assess treatment value in hepatitis C.
Am J Manag Care
December 2023
PRECISIONheor, 2 Bethesda Metro Center, Ste 850, Bethesda, MD 20814. Email:
Objectives: To estimate the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) compared with peginterferon alfa and ribavirin (PEG/riba) employing a generalized cost-effectiveness analysis (GCEA).
Study Design: To assess the societal-level cost-effectiveness of DAA treatment for HCV, we extended a previously published discrete-time Markov simulation model of HCV transmission and progression to include market dynamics and broader elements of value.
Methods: We followed a stepwise process to add novel value elements to a traditional CEA model for HCV treatments.
Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
PLoS One
December 2022
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Article Synopsis
- - The study evaluated the effectiveness of Sofosbuvir (SOF)-based treatments for chronic hepatitis C in Spain from 2015-2019, showing improved patient outcomes compared to older therapies like peginterferon and ribavirin.
- - SOF-based regimens yielded a sustained virological response (SVR) of 93-98% and significantly reduced complications such as decompensated cirrhosis (by 89%) and liver-related mortality (by 82%), while also providing substantial cost savings.
- - Overall, the findings support SOF-based treatments as a cost-effective solution that enhances health outcomes for HCV patients in Spain, aligning with global health objectives set by the WHO.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!